Cancer Research
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor Xerna™ TME Panel biomarker subtype and treatment response Excerpt from the Press Release: WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company…
Read More
The goal is first-in-human use of NaNots™, injectable absorptive nanoparticles that treat cancer via clearance of tumor-generated immune inhibitors from blood. Excerpt from the Press Release: MILL VALLEY, Calif.–(BUSINESS WIRE)–NaNotics LLC, a biopharmaceutical company developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration…
Read More
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 months with nivolumab combined with ipilimumab – Excerpt from the Press…
Read More
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). BMF-219 displayed single agent potency, surpassing greater than 90% inhibition at clinically relevant exposures in both DLBCL and MM cell lines and patient-derived samples. A Trial…
Read More
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3), patients with cirrhosis also had improved markers of liver injury, glucose metabolism, and lipid metabolism Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022…
Read More
Company Develops A Two-Step Sequential Approach Excerpt from the Press Release: SAN DIEGO, Aug. 25, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T…
Read More
SpIntellx, Inc., a leader in spatially intelligent biology, and iCura Diagnostics, a leading contract research organization (CRO) focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, today announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics. Excerpt from…
Read More
First round of Innovation to Implementation Supplement (I2IS) grants awarded to five promising research projects taking unique approaches to addressing cancer. Excerpt from the Press Release: August 11, 2022, TORONTO – Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer. “We are excited…
Read More
– Efficacy Observed with QINLOCK® was Comparable to Sunitinib with a More Favorable Safety and Tolerability Profile in GIST Patients Previously Treated with Imatinib – Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer,…
Read More